Humanized antibodies are engineered antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibodies produced naturally in humans, thereby reducing immunogenicity when used as therapeutics. This technology is crucial in the development of monoclonal antibody therapies for various diseases, as it combines the specificity of animal-derived antibodies with the reduced risk of immune rejection in humans.